問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Far Eastern Memorial Hospital (在職)

Division of Nephrology

更新時間：2023-09-19

楊如燁
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

19Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊如燁

List

35Cases

2020-04-01 - 2023-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
15Sites

Not yet recruiting9Sites

Terminated6Sites

2021-03-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2026-06-01 - 2028-12-31

Phase III

Not yet recruiting
A randomized, double-blind, parallel-group, phase 3 trial was conducted to evaluate the efficacy, safety, and tolerability of elecoglipron compared to placebo in adult patients with type 2 diabetes, impaired renal function, and receiving background treatment with dapagliflozin (Eluminate-4).

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    Dapagliflozin Elecoglipron

Participate Sites
12Sites

Not yet recruiting1Sites

2026-10-01 - 2030-03-31

Phase II/III

Not yet recruiting
A sequential phase 2/3 trial, initially a single-arm, open-label trial in adults, followed by a randomized, placebo-controlled, double-blind, multicenter trial in adults and adolescents, will evaluate the efficacy and safety of Pegcetacoplan in treating focal segmental glomerulosclerosis.

  • Condition/Disease

    Focal segmental glomerulosclerosis

  • Test Drug

    Pegcetacoplan (APL-2) 1080 mg in 20 mL (54 mg/mL) or Placebo solution Pegcetacoplan (APL-2) 1080 mg in 20mL (54mg/ml) solution

Participate Sites
5Sites

Not yet recruiting5Sites

2024-03-15 - 2031-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting9Sites

2026-01-01 - 2031-09-18

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants with Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  • Condition/Disease

    Atherosclerosis Cardiovascular Disease Chronic Kidney Disease

  • Test Drug

    Orforglipron (LY3502970) Placebo

Participate Sites
15Sites

Not yet recruiting1Sites

2024-12-01 - 2030-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2026-06-01 - 2031-06-30

Phase III

Not yet recruiting
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)

  • Condition/Disease

    Chronic Kidney Disease

  • Test Drug

    錠劑 膜衣錠

Participate Sites
14Sites

Recruiting14Sites

2026-08-15 - 2030-12-31

Phase III

Not yet recruiting
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)

  • Condition/Disease

    Renal Insufficiency, Chronic

  • Test Drug

    膠囊劑 錠劑

Participate Sites
16Sites

Not yet recruiting16Sites

2025-11-01 - 2030-12-31

Phase III

Active
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants

  • Condition/Disease

    Focal Segmental Glomerulosclerosis

  • Test Drug

    膜衣錠 膜衣錠

Participate Sites
9Sites

Recruiting9Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB